Oliver Bähr

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

David A. Reardon, Alba A. Brandes, Antonio Omuro et al. · JAMA Oncology · 2020 · 1.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial

Antonio Omuro, Alba A. Brandes, Ahmed Idbaïh et al. · Neuro-Oncology · 2022 · 485 citations · Full text

Medicine, Oncology, Radiation Oncology +17

<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner et al. · Clinical Cancer Research · 2015 · 318 citations · Full text

Medicine, Oncology, Pharmacology +17

ERGO: A pilot study of ketogenic diet in recurrent glioblastoma

Johannes Rieger, Oliver Bähr, Gabriele D. Maurer et al. · International Journal of Oncology · 2014 · 277 citations · Full text

Medicine, Nutrition, Oncology +15